IART Integra LifeSciences Holdings
XNAS
11.99
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
IART
$11.99
—
Key stats
$11.99
- 52-Week Range
- $8.70 – $20.49
- YTD
- -0.17%
- IV Rank (30D)
- 66.16
- Straddle Price
- $2.55
- P/C Vol Ratio
- 0.68
- Market Cap
- $0.9B
- Open
- $12.25
- Day Range
- $11.72 – $12.25
- Volume
- 1,431,837
- Prev Close
- $12.10
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.18 |
| Cost of Equity (CAPM) | 11.24% (VRP-adj) |
| WACC | 7.43% |
| Volatility Risk Premium | +9.4pp (IV − HV30), ERP adj +32bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -5.5% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $0.1B |
| Return on Equity (TTM) | 1.2% |
| Book / Price | 113.6% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 52.4% |
| FCF Margin (TTM) | 5.2% |
| Debt / Equity | 1.67 |
| Quality Score | 2/6 — normal (10y DCF) |
| Market-Implied Growth | +7.8% (reverse-DCF on current price) |
| SMA 50 | $15.22 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $13.54 |
| Bollinger Width / SMA20 | 286.3% (drives anchor stability) |
| Net Debt | $1.5B |
| Market Cap | $1B |
Peers used for multiples: ALKS, BIIB, NBIX
(filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
$52.63
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $-5.71 | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $7.54 | 18% | median 44.4× · 3 peers |
| Peer EV/EBITDA | $36.02 | 23% | median 19.1× · 3 peers |
| Peer P/B | $54.01 | 30% | median 3.9× · 3 peers |
| Peer P/S | $91.78 | 30% | median 4.3× · 3 peers |
| Market Anchor (SMA50) | $15.22 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $11.59 | 0% | 7 strikes · skew +0.40 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
- Exchange
- XNAS
- Market Cap
- $0.9B
- Employees
- 4,427
- List Date
- 1995-08-16
- CIK
- 0000917520
- Headquarters
- Princeton, NJ
- Homepage
- https://www.integralife.com
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 5.44% | -5.36% | 2.85% | -7.17% | 13.38% | -7.24% | 0.32% |
| Feb | 2.55% | 4.24% | -5.04% | -9.80% | -10.73% | 1.97% | -2.80% |
| Mar | -0.49% | -3.11% | 4.72% | -1.50% | -2.18% | -9.68% | -2.04% |
| Apr | 8.81% | -8.06% | -2.69% | -15.99% | -24.16% | 10.14% | -5.33% |
| May | -6.76% | 3.54% | -31.78% | 5.89% | -22.99% | 46.48% | -0.94% |
| Jun | -0.19% | -11.21% | 7.05% | -8.54% | -0.41% | 14.61% | 0.22% |
| Jul | 4.72% | 0.07% | 10.90% | -14.36% | -0.83% | -8.47% | -1.33% |
| Aug | 5.97% | -16.11% | -5.36% | -17.35% | 22.91% | -5.37% | -2.55% |
| Sep | -9.91% | -10.78% | -10.69% | -5.71% | -5.47% | -2.05% | -7.43% |
| Oct | -4.47% | 14.62% | -5.39% | 7.20% | -18.47% | -25.48%* | -5.33% |
| Nov | -4.85% | 7.83% | 6.35% | 27.49% | 14.19% | -- | 10.20% |
| Dec | 7.24% | -0.51% | 6.17% | -7.73% | -4.90% | -- | 0.05% |
| Total | 6.18% | -25.59% | -27.22% | -43.52% | -41.25% | -0.13% | -21.92% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $13.31
SMA 50: $15.11
SMA 200: $14.07
Current: $11.99
EMA 12: $12.76
EMA 26: $13.67
MACD: -0.9109 | Signal: -0.0728
BEARISH
ADX (14): 32.87
TREND
+DI: 11.63
−DI: 32.66
Momentum Oscillators
RSI (14): 34.48
NEUTRAL
Stoch %K: 15.87
Stoch %D: 17.55
Williams %R: -84.50
Volume & Volatility
BB Upper: $15.60
BB Lower: $11.02
NEUTRAL
OBV: 15,752,716
Vol SMA 20: 1,271,325
Vol ROC: 73.97%
ATR: $0.75
True Range: $0.53
HV 20: 102.2%
HV 30: 88.3%
HV 60: 65.7%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-29T00:00:00 – 2026-10-27T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
This report provides a comprehensive analysis of IART, a regenerative medicine company. Our assessment is BULLISH with a confidence level of 7 out of 10.
Key drivers:
- Strong momentum signals from MACD and EMA
- Positive news sentiment from recent headlines
- Growing trend in regenerative medicine industry
Primary risks:
- High volatility, making it a high-risk stock
- Regulatory changes or setbacks could impact the company's growth
Investment thesis: IART is well-positioned to capitalize on the growing demand for regenerative medicine products. The company's strong momentum signals and positive news sentiment suggest that it may continue to trend upward in the near term.
Recent news sentiment impact: The recent headlines have been overwhelmingly positive, highlighting the company's advancements in tissue engineering and regenerative medicine. This has contributed to the bullish sentiment surrounding IART.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Bullish, Medium-term (1-3 months): Bullish, Long-term (3-12 months): Neutral
Support/Resistance Levels:
- Upper Bollinger Band: $18.75
- Middle Bollinger Band: $17.23
- Lower Bollinger Band: $15.71
Momentum Signals: RSI interpretation: 68.05 (neutral), indicating that the stock is not overbought or oversold.
MACD signal: Bullish, with a strong crossover above the signal line.
Bollinger Bands position: Neutral, as the price is near the middle band.
Volume Analysis: Volume SMA 20: 895549.86, indicating increasing volume and institutional interest.
News & Sentiment Analysis
Recent Headlines Summary: The recent headlines have been overwhelmingly positive, highlighting the company's advancements in regenerative medicine and tissue engineering.
Sentiment Assessment: Positive news sentiment dominates, with a score of +3 out of 5.
Catalyst Identification: Upcoming regulatory approvals or product launches could drive further growth.
Market Narrative: The positive news sentiment aligns with the technical signals, indicating a strong uptrend.
Risk & Volatility Assessment
Beta Interpretation: High risk (beta = 2.06), indicating that the stock moves more than the market.
Volatility Regime: Current volatility is high, making it a high-risk investment.
Options Market Signals: IV rank: 8.5% (low), indicating historically low volatility; put/call ratios indicate bearish sentiment.
Downside Protection: Support levels are strong at $17.23 and $15.71, providing a cushion for potential price drops.
Market Context & Positioning
Sector Performance: Regenerative medicine sector is trending upward, with IART outperforming the broader market.
Institutional Activity: Volume patterns suggest increasing institutional interest, supporting the bullish sentiment.
Correlation Analysis: Correlation with SPY = 0.42, indicating a moderate correlation between the two indices.
Relative Valuation: The stock is trading near its upper Bollinger Band, suggesting it may be overbought in the short term.
Key Levels & Action Items
Critical Price Levels: Support levels at $17.23 and $15.71; resistance level at $18.75.
Breakout/Breakdown Levels: Breakout above $19.50 or breakdown below $16.50 could trigger significant moves.
Time-Sensitive Catalysts: Upcoming regulatory approvals or product launches could drive further growth.
Risk Management: Consider setting stop-loss levels near the support levels ($17.23 and $15.71) to manage potential downside risk.
This comprehensive analysis provides a detailed assessment of IART, highlighting both bullish and bearish cases. The report highlights key drivers, primary risks, and market context, providing investors with a framework for making informed investment decisions.
Generated
News
All IART news →
Cincinnati flooding hit revenue, but neurosurgery growth and refinancing support recovery.
Showing 1–10 of 11
Page 1 of 2
Earnings History
14 of 19 under expected move
Avg Expected Move
14.47%
Avg Actual Move
8.98%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-11-02 | Pre-Market | 4.61% | 8.99% | 1.95x | Exceeded |
| 2022-04-27 | Pre-Market | 5.03% | 2.44% | 0.49x | Within |
| 2022-07-27 | Pre-Market | 5.86% | 1.12% | 0.19x | Within |
| 2023-01-10 | Pre-Market | 8.89% | 0.19% | 0.02x | Within |
| 2023-04-26 | Pre-Market | 10.79% | 7.89% | 0.73x | Within |
| 2023-07-27 | Pre-Market | 7.60% | 2.22% | 0.29x | Within |
| 2023-10-25 | Pre-Market | 11.02% | 4.99% | 0.45x | Within |
| 2024-02-28 | Pre-Market | 5.65% | 12.65% | 2.24x | Exceeded |
| 2024-05-06 | Pre-Market | 19.83% | 19.90% | 1.00x | Exceeded |
| 2024-07-29 | Pre-Market | 20.84% | 19.12% | 0.92x | Within |
| 2024-11-04 | After-Close | 9.95% | 3.28% | 0.33x | Within |
| 2025-02-25 | After-Close | 12.94% | 4.53% | 0.35x | Within |
| 2025-05-05 | Pre-Market | 20.92% | 21.19% | 1.01x | Exceeded |
| 2025-07-31 | Pre-Market | 21.02% | 6.22% | 0.30x | Within |
| 2025-10-30 | Pre-Market | 24.79% | 23.46% | 0.95x | Within |
| 2026-02-26 | After-Close | 22.51% | 0.44% | 0.02x | Within |
| 2026-05-05 | Pre-Market | 17.14% | 24.13% | 1.41x | Exceeded |
| 2026-07-29 | After-Close | 17.74% | 3.82% | 0.22x | Within |
| 2026-10-21 | After-Close | 27.87% | 4.10% | 0.15x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
IART Options Activity & IV Rank
IART IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 87.4%
7-DTE IV: —
Expected Move: $2.55
7-DTE Move: $2.55
Days to Exp: 24 (2026-11-20)
Options Flow
Call Volume: 22
Put Volume: 15
P/C Volume: 0.682
BULLISH
Call OI: 57
Put OI: 77
P/C OI: 1.351
Total OI: 134
ATM Options Pricing
ATM Call: $1.18
ATM Put: $1.38
Call %: 9.8%
Put %: 11.5%
Chain Summary
Chain Volume: 391
Chain OI: 1,614
Last Updated: 10/27/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 15th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
15%
vs own history
GEX tilt
+0.43
OI-weighted, today
Vanna tilt
+0.44
δ-sensitivity to IV
Charm tilt
-0.53
δ-decay vs time
Vanna tilt +0.44: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.53: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 4 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 120.6% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)66.2MediumOct 27
Straddle Price (30 DTE)$2.55Oct 27
Beta Analysis
Risk Metrics
Beta: 1.7337
Alpha: -28.81%
Correlation: 0.3414
R-Squared: 11.7%
Stock Volatility: 64.5%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own IART
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Millennium Management Hedge fund Izzy Englander | $25.9M | #970 of 3716 | +131.2% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $189K | #2892 of 3138 | new | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $13K | #3891 of 4729 | -31.2% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
IART Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 77,618,250 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
1 filers$10.78K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Simplex Trading, LLC Custodian | $10.78K | 100.00% | 2026-06-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|
IART Insider Trading (Form 4)
Latest: 2026-09-04Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-04 | Chantal Veillon-Berteloot | EVP & CHRO | Tax (F) | −1,455 | $16.62 | -$24.2K | EDGAR |
| 2026-07-06 | Robert T. Davis Jr. | EVP & President, TR&DT | Grant (A) | +11,180 RSU | — | EDGAR | |
| 2026-07-06 | Jeffrey Mosebrook | SVP, Fin & Princ Acct Officer | Tax (F) | −937 | $17.89 | -$16.8K | EDGAR |
| 2026-07-06 | Harvinder Singh | EVP & President, SS | Grant (A) | +5,590 RSU | — | EDGAR | |
| 2026-07-06 | Lea Daniels Knight | EVP & Chief Financial Officer | Tax (F) | −5,226 | $18.05 | -$94.3K | EDGAR |
| 2026-06-03 | Stuart Essig | President and CEO | Grant (A) | +1,070,765 opt | — | EDGAR | |
| 2026-06-03 | Michael J. McBreen | EVP & Chief Commercial Officer | Grant (A) | +92,281 opt | — | EDGAR | |
| 2026-05-11 | Renee Wonlai Lo | Director | Grant (A) | +17,700 RSU | — | EDGAR | |
| 2026-05-11 | Shaundra Clay | Director | Grant (A) | +17,700 RSU | — | EDGAR | |
| 2026-05-11 | Keith Bradley | Director | Tax (F) | −882 | $13.92 | -$12.3K | EDGAR |
| 2026-05-11 | Christian S Schade | Director | Grant (A) | +17,700 RSU | — | EDGAR | |
| 2026-05-11 | Jeffrey A Graves | Director | Grant (A) | +17,700 RSU | — | EDGAR | |
| 2026-05-11 | Barbara B Hill | Director | Award (A) | +24,338 | — | EDGAR | |
| 2026-03-12 | Michael Damon Hutchinson | EVP, Chief Legal Officer & Sec | Grant (A) | +70,305 RSU | — | EDGAR | |
| 2026-03-12 | Lea Daniels Knight | EVP & Chief Financial Officer | Tax (F) | −8,089 | $9.61 | -$77.7K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
IART Insider Holdings
15 insiders · @ $11.99
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Stuart Essig | President and CEO | 1,152,236 | $13.82M | -$149.39M | 67 | 2026-06-03 |
| 2 | Barbara B Hill | Director | 169,841 | $2.04M | $1.95M | 17 | 2026-05-11 |
| 3 | Christian S Schade | Director | 90,034 | $1.08M | -$2.54M | 25 | 2026-05-11 |
| 4 | Keith Bradley | Director | 88,254 | $1.06M | -$2.66M | 62 | 2026-05-11 |
| 5 | Robert T. Davis Jr. | EVP & President, TR&DT | 74,874 | $897.7K | -$3.55M | 40 | 2026-07-06 |
| 6 | Michael J. McBreen | EVP & Chief Commercial Officer | 60,743 | $728.3K | -$964.0K | 25 | 2026-06-03 |
| 7 | Eric Schwartz | EVP, Chief Legal Officer & Sec | 56,020 | $671.7K | -$697.1K | 24 | 2025-03-13 |
| 8 | Lea Daniels Knight | EVP & Chief Financial Officer | 45,263 | $542.7K | $0 | 7 | 2026-07-06 |
| 9 | Shaundra Clay | Director | 41,515 | $497.8K | $0 | 6 | 2026-05-11 |
| 10 | Jeffrey A Graves | Director | 41,086 | $492.6K | $102.2K | 5 | 2026-05-11 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
IART Board & Officers
As of SEC filings through Oct 13, 2026Directors 7
- Keith Bradley · on file since 2006
- Christian S Schade · since May 17, 2006
- Stuart Essig · listed since Nov 2010
- Barbara B Hill · since May 22, 2013
- Shaundra Clay · since Apr 1, 2021
- Renee Wonlai Lo · since Jul 18, 2022
- Jeffrey A Graves · since Dec 12, 2023
Officers 10
- Michael J. McBreen · EVP & President, CSS · listed since Aug 2020
- Robert T. Davis Jr. · EVP & President, TT · listed since Feb 2021
- Harvinder Singh · EVP & President, International · listed since Mar 2024
- Lea Daniels Knight · EVP & Chief Financial Officer · since Jun 28, 2023
- Michael Damon Hutchinson · EVP, Chief Legal Officer & Sec · since Jan 27, 2026
- Lesha R Shinn · CVP, Chief Legal Officer & Sec · since Sep 17, 2026
- Chantal Veillon-Berteloot · EVP & CHRO · since Aug 23, 2023
- Jeffrey Mosebrook · SVP, Fin & Princ Acct Officer · listed since Feb 2024
- Stuart Essig · Exec. Chairman of the Board · listed since May 2024
- Andrea B Caruso · Cvp & CHRO · since Oct 1, 2026
Changes in the last 10 years (44)
| Oct 1, 2026 | Andrea B Caruso became Cvp & CHRO |
| Sep 17, 2026 | Lesha R Shinn became CVP, Chief Legal Officer & Sec |
| Apr 30, 2026 | The company announced the departure of Mojdeh Poul from the board in an SEC filing |
| Apr 30, 2026 | The company announced the departure of Mojdeh Poul as President & CEO in an SEC filing |
| Jan 27, 2026 | Michael Damon Hutchinson became EVP, Chief Legal Officer & Sec |
| Jan 6, 2025 | Mojdeh Poul became a director |
| Jan 6, 2025 | Mojdeh Poul became President & CEO |
| Nov 4, 2024 | The company announced the departure of Jan De Witte from the board in an SEC filing |
| Nov 4, 2024 | The company announced the departure of Jan De Witte as President & CEO in an SEC filing |
| May 13, 2024 | Stuart Essig first listed as Exec. Chairman of the Board in an SEC filing |
| Mar 12, 2024 | Harvinder Singh listed as EVP & President, International (previously Exec VP & PRES, International) in SEC filings |
| Feb 22, 2024 | Jeffrey Mosebrook listed as SVP, Fin & Princ Acct Officer (previously SVP, Fin & PAO) in SEC filings |
| Dec 12, 2023 | Jeffrey A Graves became a director |
| Aug 23, 2023 | Chantal Veillon-Berteloot became EVP & CHRO |
| Jul 6, 2023 | Jeffrey Mosebrook listed as SVP, Fin & PAO (previously SVP, Fin, PFO & PAO) in SEC filings |
| Jun 28, 2023 | Lea Daniels Knight became EVP & Chief Financial Officer |
| Feb 15, 2023 | Jeffrey Mosebrook listed as SVP, Fin, PFO & PAO (previously SVP, Fin & Princ Acct Officer) in SEC filings |
| Jan 25, 2023 | The company announced the departure of Carrie L Anderson as Executive Vice President & CFO in an SEC filing |
| Oct 3, 2022 | Harvinder Singh became Exec VP & PRES, International |
| Sep 23, 2022 | The company announced the departure of Glenn Coleman as Executive Vice President & COO in an SEC filing |
| Jul 18, 2022 | Renee Wonlai Lo became a director |
| Dec 1, 2021 | Jan De Witte became a director |
| Dec 1, 2021 | Jan De Witte became President & CEO |
| Oct 28, 2021 | The company announced the departure of Peter J Arduini from the board in an SEC filing |
| Oct 28, 2021 | The company announced the departure of Peter J Arduini as President & CEO in an SEC filing |
| Apr 1, 2021 | Shaundra Clay became a director |
| Feb 26, 2021 | Robert T. Davis Jr. listed as EVP & President, TT (previously Cvp,pres-Ortho & Tissue Tech) in SEC filings |
| Dec 4, 2020 | Eric Schwartz listed as EVP, Chief Legal Officer & Sec (previously Corp VP, Gen Counsel & Sec) in SEC filings |
| Nov 10, 2020 | Lisa Evoli listed as Executive Vice President &CHRO (previously Chief Human Resources Officer) in SEC filings |
| Sep 16, 2020 | Tru St Partnership, L.P. became a 10% owner |
| Aug 13, 2020 | Glenn Coleman listed as Executive Vice President & COO (previously Cvp, Chief Operating Officer) in SEC filings |
| Aug 4, 2020 | Michael J. McBreen listed as EVP & President, CSS (previously Executive VP & President, CSS) in SEC filings |
| Jul 7, 2020 | Jeffrey Mosebrook listed as SVP, Fin & Princ Acct Officer (previously Principal Accounting Officer) in SEC filings |
| Jul 2, 2020 | Carrie L Anderson listed as Executive Vice President & CFO (previously CVP, Chief Financial Officer) in SEC filings |
| Jun 8, 2020 | Michael J. McBreen became Executive VP & President, CSS |
| Jul 2, 2019 | Glenn Coleman listed as Cvp, Chief Operating Officer (previously Cvp, Chief Financial Officer) in SEC filings |
| Jun 24, 2019 | Carrie L Anderson became CVP, Chief Financial Officer |
| Jan 9, 2019 | Rhonda Germany Ballintyn became a director |
| Nov 12, 2018 | Eric Schwartz became Corp VP, Gen Counsel & Sec |
| Mar 12, 2018 | Richard E Caruso no longer listed as a director in SEC filings |
| Feb 20, 2018 | Daniel L. Reuvers listed as Cvp,pres - Codman Spc Surgical (previously Cvp,pres-Spc Surgical Solution) in SEC filings |
| Oct 17, 2017 | Jeffrey Mosebrook became Principal Accounting Officer |
| Dec 5, 2016 | Robert T. Davis Jr. listed as Cvp,pres-Ortho & Tissue Tech (previously Corp VP, Spc Surgica Solutions) in SEC filings |
| Dec 5, 2016 | Daniel L. Reuvers listed as Cvp,pres-Spc Surgical Solution (previously Corp VP, Pres. International) in SEC filings |
Not reported recently (15)
- Eric Schwartz · Last reported as EVP, Chief Legal Officer & Sec in an SEC filing dated Mar 13, 2025
- Raymond G. Murphy · Last reported as a director in an SEC filing dated May 13, 2024
- Lisa Evoli · Last reported as Executive Vice President &CHRO in an SEC filing dated Mar 14, 2023
- Donald E Morel Jr · Last reported as a director in an SEC filing dated May 17, 2022
- Tru St Partnership, L.P. · Last reported as a 10% owner in an SEC filing dated Mar 25, 2022
- Rhonda Germany Ballintyn · Last reported as a director in an SEC filing dated May 17, 2021
- Richard E Caruso · Last reported as a 10% owner in an SEC filing dated Jun 22, 2020
- Lloyd Howell Jr · Last reported as a director in an SEC filing dated May 15, 2020
- Daniel L. Reuvers · Last reported as Cvp,pres - Codman Spc Surgical in an SEC filing dated May 13, 2020
- Judith Ogrady · Last reported as CorpVP,Global Reg.Affairs in an SEC filing dated Feb 18, 2020
- John Mooradian · Last reported as Corp VP, Global Ops & Supp Chn in an SEC filing dated Feb 18, 2020
- Kenneth Burhop · Last reported as Corpvp,chiefscientific Officer in an SEC filing dated Feb 18, 2020
- Joseph Vinhais · Last reported as Corp VP,Global Qlty Assurance in an SEC filing dated Sep 13, 2019
- James M Sullivan · Last reported as a director in an SEC filing dated May 21, 2018
- Richard D. Gorelick · Last reported as Corp VP, Gen Counsel & Sec in an SEC filing dated Mar 27, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
IART Proposed Insider Sales (Form 144)
Latest: 2024-12-03
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2024-12-03 | Schwartz Eric | Officer | 4,070 | $100.1K | 2024-12-03 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2024-03-06 | DAVIS ROBERT T. JR. | Officer | 8,348 | $305.5K | 2024-03-06 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2023-08-09 | Mosebrook Jeffrey | Officer | 1,177 | $52.3K | 2023-08-09 | ETRADE FINANCIAL CORPORATION | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
81 ETFs hold IART
25 shown · $246.40M total exposure · 0.04% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | IJR iShares Core S&P Small-Cap ETF | iShares (BlackRock) | 0.05% | $46.9M | $104.0B | 2026-10-23 |
| 2 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $34.3M | — | 2026-09-30 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.01% | $24.2M | — | 2026-09-30 |
| 4 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.03% | $20.4M | $74.6B | 2026-10-23 |
| 5 | VBR Vanguard Morningstar Small-Cap Value ETF | Vanguard | 0.02% | $15.8M | — | 2026-09-30 |
| 6 | DFSV Dimensional US Small Cap Value ETF | Dimensional | 0.05% | $12.9M | — | 2026-10-23 |
| 7 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $12.2M | — | 2026-09-30 |
| 8 | FNDA Schwab Fundamental U.S. Small Company ETF | Nport | 0.12% | $10.7M | — | 2026-05-31 |
| 9 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.06% | $7.6M | $13.9B | 2026-10-23 |
| 10 | SPSM State Street® SPDR® Portfolio S&P 600™ Small Cap ETF | SPDR (State Street) | 0.05% | $7.2M | $15.8B | 2026-10-23 |
| 11 | IJS iShares S&P Small-Cap 600 Value ETF | iShares (BlackRock) | 0.09% | $6.5M | $7.7B | 2026-10-23 |
| 12 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.04% | $6.5M | — | 2026-09-30 |
| 13 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.02% | $5.1M | — | 2026-05-31 |
| 14 | DFAT Dimensional US Targeted Value ETF | Dimensional | 0.01% | $4.3M | — | 2026-10-23 |
| 15 | SLYV State Street® SPDR® S&P 600™ Small Cap Value ETF | SPDR (State Street) | 0.09% | $4.1M | $4.8B | 2026-10-23 |
| 16 | DFAS Dimensional US Small Cap ETF | Dimensional | 0.01% | $3.9M | — | 2026-10-23 |
| 17 | VIOO Vanguard S&P Small-Cap 600 ETF | Vanguard | 0.06% | $3.8M | — | 2026-09-30 |
| 18 | IHI iShares U.S. Medical Devices ETF | iShares (BlackRock) | 0.10% | $3.7M | $3.6B | 2026-10-23 |
| 19 | VHT Vanguard Health Care ETF | Vanguard | 0.02% | $3.3M | — | 2026-09-30 |
| 20 | DFMC Dimensional US Micro Cap ETF | Dimensional | 0.03% | $2.5M | — | 2026-10-23 |
| 21 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.08% | $2.2M | — | 2026-07-31 |
| 22 | VIOV Vanguard S&P Small-Cap 600 Value ETF | Vanguard | 0.12% | $2.2M | — | 2026-09-30 |
| 23 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.00% | $2.2M | — | 2026-10-23 |
| 24 | FYX First Trust Small Cap Core AlphaDEX® Fund | First Trust | 0.14% | $1.9M | $1.4B | 2026-10-23 |
| 25 | EES WisdomTree U.S. SmallCap Fund | Nport | 0.25% | $1.8M | — | 2026-06-30 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
70.53
TTM Diluted EPS
$0.17
TTM Revenue
$1.66B
TTM Net Income
$13.01M
TTM Op. Cash Flow
$140.40M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $411.18M | $14.85M | $0.19 | $95.98M |
| Q2 '26 | 2026-06-30 | $418.76M | $4.48M | $0.06 | $22.80M |
| Q1 '26 | 2026-03-31 | $391.92M | $-4.62M | $-0.06 | $9.80M |
| Q4 '25 | 2025-12-31 | $434.93M | $-1.70M | $-0.02 | $11.82M |
| Q3 '25 | 2025-09-30 | $402.06M | $-5.40M | $-0.07 | $40.91M |
| Q2 '25 | 2025-06-30 | $415.61M | $-484.07M | $-6.31 | $8.92M |
| Q1 '25 | 2025-03-31 | $382.65M | $-25.29M | $-0.33 | $-11.26M |
| Q4 '24 | 2024-12-31 | $442.65M | $19.43M | $0.25 | $50.74M |
| Q3 '24 | 2024-09-30 | $380.83M | $-10.70M | $-0.14 | $22.48M |
| Q2 '24 | 2024-06-30 | $418.18M | $-12.40M | $-0.16 | $40.40M |
| Q1 '24 | 2024-03-31 | $368.87M | $-3.28M | $-0.04 | $15.76M |
| Q4 '23 | 2023-12-31 | $397.04M | $19.83M | $0.25 | $58.75M |
Q3 2026 • period ending 2026-09-30 • filed 2026-10-23
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
0.89
P/S
0.56
EV/EBITDA
11.59
EV/Sales
1.54
ROE
-0.7%
ROA
-0.2%
Div Yield
0.00%
FCF Yield
9.23%
Debt/Equity
1.75
Current Ratio
—
Market Cap
$924.86M
as of 2026-10-27
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
7.27M
SI % of Float
10.91%
Days to Cover
7.51
Short Vol Ratio
52.7%
Free Float
66.62M
Float %
85.7%
Short interest 2026-09-30 • Short volume 2026-10-27 • Float 2026-08-14